Cingulate Inc. (CINGW)

0.0116 0.0000 (0.00%) At close: 04:00PM EDT

Cingulate Inc.

1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Shane J. Schaffer Pharm.D., PharmD	CEO & Chairman of the Board	491.96k	N/A	1975
Dr. Laurie A. Myers M.B.A., Ph.D.	Executive VP & COO	415.17k	N/A	1957
Dr. Matthew N. Brams M.D.	Executive VP & Chief Medical Officer	244.79k	N/A	1964
Ms. Jennifer L. Callahan CPA	Senior VP & CFO	N/A	N/A	1971
Dr. Raul R. Silva M.D.	Executive VP & Chief Science Officer	N/A	N/A	1958
Thomas Dalton	Vice President of Investor & Public Relations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Corporate Governance

Cingulate Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.